Back to top
more

Innate Pharma (IPHA)

(Delayed Data from NSDQ)

$2.40 USD

2.40
521

-0.06 (-2.44%)

Updated Apr 25, 2024 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for IPHA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Innate Pharma S.A. Sponsored ADR [IPHA]

Reports for Purchase

Showing records 1 - 20 ( 27 total )

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 1

03/22/2024

Company Report

Pages: 7

Regulatory Pathway for Lacutamab Coming into Focus; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 2

12/13/2023

Daily Note

Pages: 5

Strong Data in SS Support Filing of BLA For Accelerated Approval of Lacutamab; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 3

11/15/2023

Company Report

Pages: 7

Year-End Lacutamab Updates Under the Spotlight; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 4

09/18/2023

Company Report

Pages: 7

TELLOMAK Final Readout in 2H23; ANKET-Based Programs Progressing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 5

06/16/2023

Daily Note

Pages: 5

Tellomak Analyzed With New Lymph Node Evaluation Criteria Remains Positive; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 6

05/11/2023

Company Report

Pages: 7

Focus on Lacutamab Readouts in 2H23; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 7

03/24/2023

Company Report

Pages: 7

TELLOMAK Final Readout in 2H23; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 8

11/16/2022

Company Report

Pages: 7

TELLOMAK Readout at ASH; Continued Clinical Progress; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 9

09/27/2022

Daily Note

Pages: 4

TELLOMAK Update Underscores Lacutamab''s Potential in MF; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 10

09/16/2022

Company Report

Pages: 7

Awaiting Pivotal Lacutamab Data 2H22; Pipeline Progressing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 11

05/12/2022

Company Report

Pages: 7

Monalizumab Achieved Another Milestone; TELLOMAK Readouts on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 12

03/25/2022

Company Report

Pages: 7

Pipeline Continues to Progress in 2022; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 13

12/14/2021

Company Report

Pages: 6

Positive Clinical Update on Monalizumab at ESMO-IO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 14

09/20/2021

Industry Report

Pages: 7

Durvalumab COAST Update Makes a Splash at ESMO

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 15

09/16/2021

Company Report

Pages: 7

Eyes on Monalizumab Updates; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 16

06/24/2021

Daily Note

Pages: 4

Lacutamab Shows Promise in Mycosis Fungoides; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 17

05/12/2021

Company Report

Pages: 7

Initial Lacutamab MF Data Imminent; R&D Day in Mid-2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 18

03/19/2021

Company Report

Pages: 7

Executing Pipeline Advancement Strategy; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 19

12/14/2020

Company Report

Pages: 6

Re-Prioritize R&D Over Commercialization; Adjust PT to $11.50; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Innate Pharma S.A. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 20

11/18/2020

Company Report

Pages: 7

Monalizumab Advanced Into Pivotal; COVID-19 Study Expanded; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party